250 related articles for article (PubMed ID: 25271708)
1. The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models.
Wang W; Qin JJ; Voruganti S; Srivenugopal KS; Nag S; Patil S; Sharma H; Wang MH; Wang H; Buolamwini JK; Zhang R
Nat Commun; 2014 Oct; 5():5086. PubMed ID: 25271708
[TBL] [Abstract][Full Text] [Related]
2. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
3. Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis.
Qin JJ; Wang W; Sarkar S; Zhang R
J Control Release; 2016 Sep; 237():101-14. PubMed ID: 27394681
[TBL] [Abstract][Full Text] [Related]
4. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
5. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
[TBL] [Abstract][Full Text] [Related]
6. Targeted Brain Tumor Therapy by Inhibiting the MDM2 Oncogene: In Vitro and In Vivo Antitumor Activity and Mechanism of Action.
Punganuru SR; Artula V; Zhao W; Rajaei M; Deokar H; Zhang R; Buolamwini JK; Srivenugopal KS; Wang W
Cells; 2020 Jul; 9(7):. PubMed ID: 32630235
[TBL] [Abstract][Full Text] [Related]
7. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
Xiong J; Yang Q; Li J; Zhou S
Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
[TBL] [Abstract][Full Text] [Related]
8. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
[TBL] [Abstract][Full Text] [Related]
9. Gossypol has anti-cancer effects by dual-targeting MDM2 and VEGF in human breast cancer.
Xiong J; Li J; Yang Q; Wang J; Su T; Zhou S
Breast Cancer Res; 2017 Mar; 19(1):27. PubMed ID: 28274247
[TBL] [Abstract][Full Text] [Related]
10. Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.
Lu J; McEachern D; Li S; Ellis MJ; Wang S
Mol Cancer Ther; 2016 Dec; 15(12):2887-2893. PubMed ID: 27765850
[TBL] [Abstract][Full Text] [Related]
11. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms.
Wang H; Nan L; Yu D; Agrawal S; Zhang R
Clin Cancer Res; 2001 Nov; 7(11):3613-24. PubMed ID: 11705884
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.
Kumar A; Gupta G; Bishnoi AK; Saxena R; Saini KS; Konwar R; Kumar S; Dwivedi A
Bioorg Med Chem; 2015 Feb; 23(4):839-48. PubMed ID: 25618595
[TBL] [Abstract][Full Text] [Related]
13. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.
Wang W; Qin JJ; Voruganti S; Nijampatnam B; Velu SE; Ruan KH; Hu M; Zhou J; Zhang R
Cancer Res; 2018 Oct; 78(19):5656-5667. PubMed ID: 30217928
[TBL] [Abstract][Full Text] [Related]
14. Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy.
Qin JJ; Wang W; Sarkar S; Voruganti S; Agarwal R; Zhang R
Oncotarget; 2016 May; 7(22):32566-78. PubMed ID: 27105525
[TBL] [Abstract][Full Text] [Related]
15. A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53.
Kurokawa M; Kim J; Geradts J; Matsuura K; Liu L; Ran X; Xia W; Ribar TJ; Henao R; Dewhirst MW; Kim WJ; Lucas JE; Wang S; Spector NL; Kornbluth S
Sci Signal; 2013 May; 6(274):ra32. PubMed ID: 23652204
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
[TBL] [Abstract][Full Text] [Related]
17. MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer.
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E
Breast Cancer Res; 2020 Aug; 22(1):87. PubMed ID: 32787886
[TBL] [Abstract][Full Text] [Related]
18. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
Li H; Liu Q; Wang Z; Fang R; Shen Y; Cai X; Gao Y; Li Y; Zhang X; Ye L
J Biol Chem; 2015 Sep; 290(37):22649-61. PubMed ID: 26229107
[TBL] [Abstract][Full Text] [Related]
19. Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Oct; 6(32):33106-19. PubMed ID: 26461225
[TBL] [Abstract][Full Text] [Related]
20. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
